Back
ShockWave Medical Quote, Financials, Valuation and Earnings

Global Leader In Plant Cell Biology Poised For Rapid Growth!
Click for more info and ADD THIS COMPANY TO YOUR WATCHLIST!
Sell
47
SWAV
ShockWave Medical
Last Price:
187.21
Seasonality Move:
15.31%
7 Day Trial
ALL ACCESS PASS
$
7

New Year, New Trades, Try A.I. Today
Learn to forecast trends with up to 87.4% proven accuracy -> Register HereShockWave Medical Price Quote
$187.21
-0.11 (-1.2%)
(Updated: February 4, 2023 at 4:30 AM ET)
ShockWave Medical Key Stats
Sell
47
ShockWave Medical (SWAV)
is a Sell
Day range:
$185.06 - $190.66
52-week range:
$113.36 - $320.54
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
16.19
P/B ratio:
19.02%
Volume:
374.2K
Avg. volume:
430.4K
1-year change:
30.14%
Market cap:
$6.8B
Revenue:
$237.1M
EPS:
$2.33
How Much Does ShockWave Medical Make?
-
How Much Are ShockWave Medical's Sales Annually?
SWAV Revenues are $237.1M -
How Much Profit Does ShockWave Medical's Make A Year?
SWAV net income is -$9.1M
Is ShockWave Medical Growing As A Company?
-
What Is ShockWave Medical's Growth Rate Quarterly?
Quarterly YoY revenue growth is 1.02% -
What Is ShockWave Medical's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 17.4%
ShockWave Medical Stock Price Performance
-
Did ShockWave Medical Stock Go Up Last Month?
ShockWave Medical share price went down by -2.46% last month -
Did SWAV's Share Price Rise Over The Last Year?
SWAV share price rose by 30.14% over the past 1 year
What Is ShockWave Medical 52-Week High & Low?
-
What Is ShockWave Medical’s 52-Week High Share Price?
ShockWave Medical has traded as high as $320.54 over the past 52 weeks -
What Is ShockWave Medical’s 52-Week Low Share Price?
ShockWave Medical has traded as low as $113.36 over the past 52 weeks
ShockWave Medical Price To Free Cash Flow
-
Is ShockWave Medical Stock Overvalued?
ShockWave Medical is trading at a price to free cash flow ratio of 100.49 -
Is ShockWave Medical Stock Undervalued?
ShockWave Medical EV to Free Cash Flow ratio is 94.35 -
What Is ShockWave Medical’s Price Earnings Growth Ratio?
SWAV PEG ratio is 0.00 -
Is ShockWave Medical Trading At A Premium To Earnings?
ShockWave Medical EV to EBIT ratio is 72.25
Is It Risky To Buy ShockWave Medical?
-
How Much Debt Does ShockWave Medical Have?
Total long term debt quarterly is $14.9M -
How Much Cash Does ShockWave Medical Have?
Cash and short term investments quarterly total is $250.7M -
What Is ShockWave Medical’s Book Value Per Share?
Book value per share is 9.85
Is ShockWave Medical Cash Flow Positive?
-
What Is SWAV Cash Flow From Operations?
Cash flow from operations (TTM) is $86.1M -
What Is ShockWave Medical’s Cash Flow From Financing?
Cash flow from financing (TTM) is $3.9M -
What Is ShockWave Medical’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$50M
ShockWave Medical Return On Invested Capital
-
Is Management Doing A Good Job?
SWAV return on invested capital is 29.85% -
What Is ShockWave Medical Return On Assets?
ROA measures how assets are converting to revenues and is 23.04% -
What Is SWAV Return On Equity?
ROE is a measure of profitability and is 31.64%
ShockWave Medical Earnings Date & Stock Price
-
What Is ShockWave Medical's Stock Price Today?
A single share of SWAV can be purchased today for 187.32 -
What Is ShockWave Medical’s Stock Symbol?
ShockWave Medical trades on the nasdaq under the ticker symbol: SWAV -
When Is ShockWave Medical’s Next Earnings Date?
The next quarterly earnings date for ShockWave Medical is scheduled on February 16, 2023 -
When Is SWAV's next ex-dividend date?
ShockWave Medical's next ex-dividend date is February 4, 2023 -
How To Buy ShockWave Medical Stock?
You can buy ShockWave Medical shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
ShockWave Medical Competitors
-
Who Are ShockWave Medical's Competitors?
Below is a list of companies who compete with ShockWave Medical or are related in some way:
ShockWave Medical Dividend Yield
Data Unavailable
ShockWave Medical Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 1740% | 47.44% |
Revenue: | 101.57% | 6.09% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 1 |
Price Target: | 243.25 |
Upside from Last Price: | 29.86% |